Saturday, November 16, 2024
- 10:30AM-12:30PM
-
Abstract Number: 0149
Beliefs on Self-Management in Rheumatoid Arthritis Compared to Other Chronic Diseases Using the Nationally Representative Medical Expenditure Panel Survey
Epidemiology & Public Health Poster I- 10:30AM-12:30PM
-
Abstract Number: 0665
Belimumab Induces Early and Sustained Resolution of Lupus Thrombocytopenia and Lupus Arthritis
SLE – Treatment Poster I- 10:30AM-12:30PM
-
Abstract Number: 0004
Beyond Antibodies and CAR-T: Topologically Engineered, Superdimeric Antibody NK Engagers and T Cell Engagers for B Cell Depletion Demonstrating Cooperative Binding to Target and Effector Cells
B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster- 10:30AM-12:30PM
-
Abstract Number: 0031
Beyond Pain and Inflammation: Intra-articular Liraglutide’s Comprehensive Benefits on Synovial Health and Cartilage in Osteoarthritis Compared to Dexamethasone
Osteoarthritis & Joint Biology – Basic Science Poster- 10:30AM-12:30PM
-
Abstract Number: 0191
Beyond the Symptoms: Exploring Cognitive Bias in Lupus Diagnosis Within Primary Care
Healthcare Disparities in Rheumatology Poster I- 10:30AM-12:30PM
-
Abstract Number: 0602
Bimekizumab Impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Core Domains for Patients with Psoriatic Arthritis: Results up to 2 Years of Treatment Duration
SpA Including PsA – Treatment Poster I- 10:30AM-12:30PM
-
Abstract Number: 0591
Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
SpA Including PsA – Treatment Poster I- 10:30AM-12:30PM
-
Abstract Number: 0597
Bimekizumab Maintained Stringent Clinical Responses over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
SpA Including PsA – Treatment Poster I- 10:30AM-12:30PM
-
Abstract Number: 0600
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies
SpA Including PsA – Treatment Poster I- 10:30AM-12:30PM
-
Abstract Number: 0110
Binding Characteristics of Patient Clusters Among Anticardiolipin and Anti-β2-Glycoprotein I ELISA and Non-ELISA Assays: A Survey by the Association of Medical Laboratory Immunologists
Antiphospholipid Syndrome Poster- 10:30AM-12:30PM
-
Abstract Number: 0401
Biologic Abatement and Capturing Kids Outcomes and Flare Frequency in Juvenile Spondyloarthritis: Baseline Characteristics and Enrollment
Pediatric Rheumatology – Clinical Poster I- 10:30AM-12:30PM
-
Abstract Number: 0485
Biomarkers for Disease Activity and Response to Treatment in Early Rheumatoid Arthritis: Metabolomics and Machine Learning Analyses in NORD-STAR Cohort
RA – Diagnosis, Manifestations, & Outcomes Poster I- 10:30AM-12:30PM
-
Abstract Number: 0039
Blockade of Soluble and Cell Surface PAD Activity Prevents the Generation of Citrullinated Autoantigens Recognized by RA Patients’ Serum
RA – Etiology & Pathogenesis Poster- 10:30AM-12:30PM
-
Abstract Number: 0215
BP Connect Improves Follow-up of High Blood Pressure in Urban Rheumatology and Non-Rheumatology Clinics